[1] CocaPelaz A, Rodrigo JP, Bradley PJ, et al. Adenoid cystic carcinoma of the head and neck—an update[J]. Oral Oncol, 2015, 51(7): 652-661. DOI: 10.1016/j.oraloncology.2015.04.005.
[2] Damborenea Tajada J, Campos del Alamo MA, Marín García J, et al. Adenoid cystic carcinoma of the larynx. Case report and literature review[J]. An Otorrinolaringol Ibero Am, 1999, 26(3): 257-263.
[3] Amit M, Binenbaum Y, Sharma K, et al. Incidence of cervical lymph node metastasis and its association with outcomes in patients with adenoid cystic carcinoma. An international collaborative study[J]. Head Neck, 2015, 37(7): 1032-1037. DOI: 10.1002/hed.23711.
[4] 刘文胜, 唐平章, 祁永发, 等. 腭部腺样囊性癌的诊治及预后因素的探讨[J]. 中华肿瘤杂志, 2004, 26(8): 485-489. DOI: 10.3760/j.issn.0253-3766.2004.08.012.
[5] Wu D, Liang L, Nie L, et al. Efficacy, safety and predictive indicators of apatinib after multilines treatment in advanced nonsquamous nonsmall cell lung cancer: apatinib treatment in nonsquamous NSCLC[J]. Asia Pac J Clin Oncol, 2018, In press. DOI: 10.1111/ajco.12870.
[6] Hu X, Zhang J, Xu B, et al. Multicenter phase Ⅱ study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triplenegative breast cancer[J]. Int J Cancer, 2014, 135(8): 1961-1969. DOI: 10.1002/ijc.28829.
[7] Kong Y, Sun L, Hou Z, et al. Apatinib is effective for treatment of advanced hepatocellular carcinoma[J]. Oncotarget, 2017, 8(62): 105596-105605. DOI: 10.18632/oncotarget.22337. |